0000000001226342

AUTHOR

Vicente Arrarte

showing 2 related works from this author

Psychological State after an Acute Coronary Syndrome: Impact of Physical Limitations

2021

The aim of this study was to investigate how physical limitations after ACS influence patients’ quality of life and health perception. This was a longitudinal clinical study. We recruited 146 patients diagnosed with ACS. The patients performed a stress test (Bruce’s protocol) for the evaluation of physical limitations and were classified according to the test result: without physical limitations (more than 10 METS), with some physical limitations (7 to 9 METS), and with high physical limitations (less than 6 METS). Significant differences were found between the three groups immediately after the diagnosis of ACS and after a period of three months, regarding health perception, anxiety, depre…

Acute coronary syndromephysical limitationsHealth Toxicology and MutagenesisDiseaseAnxiety030204 cardiovascular system & hematologypsychological factorsVitalityArticleacute coronary syndrome03 medical and health sciences0302 clinical medicineQuality of lifeAdaptation PsychologicalmedicineHumansLongitudinal Studies030212 general & internal medicineDepression (differential diagnoses)Depressionbusiness.industrypatient perceptionRPublic Health Environmental and Occupational Healthmedicine.diseaseAdaptation PhysiologicalTest (assessment)Distressquality of lifeMedicineAnxietymedicine.symptombusinessStress PsychologicalClinical psychologyInternational Journal of Environmental Research and Public Health
researchProduct

Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de …

2021

Different primary and secondary prevention studies have documented that a greater degree of reduction in low-density lipoprotein cholesterol (LDL-C) levels is associated with a greater decrease in cardiovascular event rates. PCSK9 inhibitors achieve important, rapid and sustained decreases in LDL-C. New clinical practice guidelines for the management of dyslipidemia establish reduced target levels of LDL-C. These goals are hardly achievable with a statin-only treatment, even in combination with ezetimibe. The addition of PCSK9 inhibitors can play a determining role in achieving these recommendations. However, it is important to identify the patient subgroups that can most benefit from this …

Secondary preventionGynecologyCardiovascular eventmedicine.medical_specialtybusiness.industryPatient subgroupsmedicine.diseaseClinical PracticeEzetimibemedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPCSK9 InhibitorsDyslipidemiaLipoprotein cholesterolmedicine.drugREC: CardioClinics
researchProduct